Systemic enzyme therapy in the gout treatment
Kovalenko V.N., Siniatchenko O.V., Ignatchenko G.A., Terzov A.I., Grin V.K., Lauschkina E.M.
Donetsk Medical Institute, Ukraine
Ukrainskii kardiologitschnyi zurnal 1998: 1, 53-56.
Abstract available in Russian.
36 male patients suffering from primary gout were observed. Patients received
non-steroidal antiinflammatory drugs (diclofenac sodium, movalis, phelden, indomethacin)
and allopurinol (milurit).
Patients were randomly divided into two groups:
Patients in the second group received Wobenzym (5 dragees 3 times a day for 1 week,
then 4x3 dragees for 7 days, and finally 3x3 dragees for 1 month) in the complex therapy.
Before therapy and after 3 weeks, purine parameters were determined in the blood –
uric acid, oxypurinol, xanthine oxidase, 5-nucleotidase, adenosine deaminase, glycine,
glutamine, and aspartic acid.
The efficacy of articular syndrome treatment in patients receiving Wobenzym reached 94.1%
in comparison to 47.3% in the control group. Even more obvious were differences regarding
renal syndrome.
While the conventional gout treatment led to the decrease of only uric acid and xanthine
oxidase in the blood, inclusion of Wobenzym into the therapy caused decrease of
oxypurinol, 5-nucleotidase and adenosine deaminase level.
Of special interest are data concerning the investigation of serum dynamic interphase
tensometry before and after treatment of patients in both groups. Administration of
allopurinol and non-steroidal antiinflammatory drugs evoked a suppression of surface
tension in the region of short, middle, and long surface life-time. This might be caused
by the accumulation of substances with surfactant properties.